Article

Host Factors Modulate Nirmatrelvir–Ritonavir Efficacy in COVID-19 Patients: A Viral Dynamics Modeling Study

2026-04-05

Abstract excerpt

Antiviral therapies such as nirmatrelvir–ritonavir are widely used for COVID-19, yet their real-world effectiveness and sources of heterogeneity in treatment response remain incompletely understood. Here, we integrate longitudinal viral load data from a large cohort of SARS-CoV-2 BA.2–infected patients in Shanghai (n=48,243) with a mechanistic within-host viral dynamics model coupled to pharmacokinetic/pharmacodyn...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e01b151a-de9f-5265-a0b0-4dfde09811af
DOI: 10.64898/2026.04.03.26350141

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Host Factors Modulate Nirmatrelvir–Ritonavir Efficacy in COVID-19 Patients: A Viral Dynamics Modeling StudyDOI 10.64898/2026.04.03.26350141Read

Integrative Modeling of SARS-CoV-2 Infection Dynamics to Inform COVID-19 Vaccination StrategiesSemantic proximity Read

Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapiesSemantic proximity Read

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read

Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory responseSemantic proximity Read

In vivo kinetics of SARS-CoV-2 infection and its relationship with a person’s infectiousnessSemantic proximity Read

Modelling SARS-CoV-2 Dynamics: Implications for TherapySemantic proximity Read

SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity Read

Incorporating the mutational landscape of SARS-COV-2 variants and case-dependent vaccination rates into epidemic modelsSemantic proximity Read

A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19Semantic proximity Read

COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomesSemantic proximity Read

From infection to immunity: understanding the response to SARS-CoV2 through in-silico modelingSemantic proximity Read

Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19Semantic proximity Read